OTCMKTS:ALSE Alseres Pharmaceuticals (ALSE) Stock Price, News & Analysis $0.0050 0.00 (0.00%) As of 10/18/2024 Add Compare Share Share Stock Analysis Stock Analysis About Alseres Pharmaceuticals Stock (OTCMKTS:ALSE) Get ALSE alerts:Sign Up Key Stats Today's Range$0.0050▼$0.005050-Day Range$0.0050▼$0.005052-Week Range$0.0050▼$0.0050VolumeN/AAverage VolumeN/AMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Alseres Pharmaceuticals, Inc. was a biotechnology company focused on developing diagnostic imaging agents and therapeutic products for disorders of the central nervous system. Its research programs addressed conditions including Parkinson’s disease, attention-deficit hyperactivity disorder and spinal cord injury. The company’s principal development program was Altropane, a molecular imaging agent designed to target dopamine transporters in the brain. The technology was investigated for its potential use in imaging-related research and the evaluation of neurological disorders. Alseres also pursued Cethrin, an experimental biologic intended to support recovery following spinal cord injury. Alseres was formerly known as Boston Life Sciences, Inc. and was based in the United States. Publicly available information about the company’s current operations, leadership and geographic activities is limited.AI Generated. May Contain Errors. Read More Receive ALSE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alseres Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ALSE Stock News HeadlinesFTSE 350 Pharmaceuticals & Biotechnology (FTNMX201030)August 12, 2023 | uk.investing.comContrast Media Contrast Agents Market Overview and Scope By 2031April 29, 2023 | marketwatch.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.October 16 at 1:00 AM | Weiss Ratings (Ad)Contrast Agents Market Growth by 2031April 12, 2023 | marketwatch.comContrast Media Contrast Agents Market Application, Product, Sales and Forecast 2023-2029March 27, 2023 | marketwatch.com2023-2028 Contrast Media & Contrast Agents Market Predictions and Growth Opportunities | Latest Research ReportMarch 21, 2023 | marketwatch.comFrom 2023 to 2029, Contrast Media or Contrast Agents Market Size | Industry GrowthMarch 16, 2023 | marketwatch.comContrast Media or Contrast Agents Market is Booming in Near Future 2023-2029March 9, 2023 | marketwatch.comSee More Headlines ALSE Stock Analysis - Frequently Asked Questions How have ALSE shares performed this year? Alseres Pharmaceuticals' stock was trading at $0.0050 at the beginning of 2026. Since then, ALSE stock has increased by 0.0% and is now trading at $0.0050. Company Calendar Today10/16/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:ALSE CIKN/A Webwww.alseres.com Phone(617) 419-3289Fax508-497-9964Employees3Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A Don't Wait for the OpenAI IPOThe AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.Get This Free Report This page (OTCMKTS:ALSE) was last updated on 10/18/2024 by MarketBeat.com Staff. From Our PartnersElon Musk’s 4th Wealth Window Set to Open by October 30Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredTrump goes "all-in" on Grand Canyon energy breakthroughA drilling crew near the Grand Canyon uncovered a clean energy well producing nearly eight times the output of...Behind the Markets | SponsoredDid you grab your copy yet?Bill Poulos's Top 10 Stocks to Buy This Quarter report is still available free, but not for long. Every quarte...Profits Run | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down ye...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alseres Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alseres Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
